Alliance Foundation Trials Opens Global Trial Investigating First-in-Class Palbociclib in HR+, HER2+ Metastatic Breast Cancer
August 22, 2017
August 22, 2017
NEW YORK, Aug. 22 -- Pfizer, a pharmaceutical company, issued the following news release:
The Alliance Foundation Trials, LLC (AFT), in conjunction with Pfizer and six international cancer research groups, today announced the launch of PATINA - a randomized, open-label, Phase 3 clinical study of the cyclin-dependent kinase 4/6 (CDK 4/6) inhibitor palbociclib (also known as IBRANCE(R)). The PATINA trial will evaluate palbociclib in combination with anti-HER2 therapy and endocrine th . . .
The Alliance Foundation Trials, LLC (AFT), in conjunction with Pfizer and six international cancer research groups, today announced the launch of PATINA - a randomized, open-label, Phase 3 clinical study of the cyclin-dependent kinase 4/6 (CDK 4/6) inhibitor palbociclib (also known as IBRANCE(R)). The PATINA trial will evaluate palbociclib in combination with anti-HER2 therapy and endocrine th . . .